Formosa Pharmaceuticals Investors
Shareholder Information
General Annual Meeting
Material Announcement
For related important information and material announcements, please refer to the Market Observation Post System (Symbol: 6838), URL : https://emops.twse.com.tw/server-java/t58query
Meeting Announcement
Meeting Agenda and Materials
Meeting Minutes
Annual Report
Prospectus
Stock Quote
Shareholder Contact
Common Share Transfer Agent and Registrar:
The Transfer Agency Department of KGI Securities
- Address: 4F, No.2, Sec. 1, Chongqing S. Rd., Taipei, Taiwan 10044, R.O.C.
- TEL: 886-2-23148800
- FAX: 886-2-23896042
- Website: https://www.kgieworld.com.tw/
News Highlight
Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals
2025-06-09
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow (Nasdaq: HROW), a leading North
